Hanmi Pharm is set to actively pursue large-scale contract manufacturing (CMO) and contract development and manufacturing (CDMO) businesses based on its biopharmaceutical development and production capabilities.
Hanmi Pharm announced on the 16th that it will participate in the '2023 Bio Europe Spring Conference' held in Basel, Switzerland, from the 20th to the 22nd, where it plans to hold business meetings with numerous global pharmaceutical companies.
Bio Europe Spring is an event where global pharmaceutical and biotech companies, along with related investors, build networks and promote partnerships. This year, around 3,000 participants from worldwide companies such as Novartis, Roche, Eli Lilly, and Pfizer are expected to attend. Hanmi Pharm will actively pursue orders by promoting the state-of-the-art large-scale manufacturing facilities (bioreactors up to 12,500 liters) at its Pyeongtaek Bio Plant, optimized for commercial production of biopharmaceuticals, as well as the specialized personnel and systems capable of operating them, through individual business meetings with each company.
As a company specializing in new drug development, Hanmi Pharm plans to grow CMO and CDMO as new growth engines through its accumulated development capabilities and large-scale biopharmaceutical manufacturing capacity. The Pyeongtaek Bio Plant currently has the production capacity to manufacture over 20 million prefilled syringe injections annually based on finished pharmaceutical products.
In particular, the second bio plant, completed in 2018, has a separate space that can flexibly expand facilities according to CMO demand, enabling flexible responses to large-scale orders. Unlike major domestic companies equipped with animal cell culture-based facilities, Hanmi Pharm emphasizes that the Pyeongtaek Bio Plant is differentiated by having manufacturing facilities using microbial culture, allowing for fast and economical mass production. It can also manufacture DNA and messenger RNA (mRNA) vaccines, which have gained renewed attention since the COVID-19 pandemic, on a large scale.
The Pyeongtaek Bio Plant produces the biopharmaceutical new drug 'Rolvedon' (Korean name Rollontis), which received FDA marketing approval in the U.S. last September, and supplies it locally in the U.S. It also supplies clinical products of a NASH treatment candidate developed by the global pharmaceutical company MSD in the U.S.
Kim Se-gwon, Director of Hanmi Pharm (Bio Manufacturing Development Team), said, "Based on the biopharmaceutical mass production and quality control capabilities confirmed through Rolvedon's entry into the U.S. market, we plan to actively expand our CMO business. We will make company-wide efforts to establish this field as a new growth engine for the Hanmi Pharm Group."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
